SmartZyme to Present at Ladenburg Thalmann 2015 Healthcare Conference

NESS ZIONA, Israel--()--SmartZyme, a biopharmaceutical company utilizing a proprietary technological platform called Provolution™ for protein design and engineering of both new and better therapeutics, today announced that management will make a corporate presentation at the Ladenburg Thalmann 2015 Healthcare Conference on September 29th at 1:30 p.m. Eastern Time. The conference is being held at the Sofitel Hotel in New York City. Doug Kohrs, chairman, Shilo Ben Zeev, chief executive officer and David Baram, Ph.D, president and chief technology will discuss the Company’s progress with its fast-acting coagulation factor for blood clotting and its progress with licensing its innovative enzyme and device for diabetic blood glucose monitoring.

About SmartZyme

SmartZyme is a privately held biopharmaceutical company focused on its Provolution™ proprietary technological platform for protein design and engineering, in accordance with industry required specifications. The company was founded in November 2013 by Shilo Ben Zeev and David Baram, Ph.D. The company aims to efficiently design and create proteins and potent enzymes with the specific characteristics required for optimal performance. For more information, visit


Shilo Ben Zeev, 646-402-1016
Kim Golodetz, 212-838-3777